Lux Capital Leads Nomic Series A
Nomic's mission is to make the human proteome as broadly and easily accessible as the human genome.
We met Dr. Milad Dagher, the founder of nomic, back in April of 2019, after Milad just finished his PhD at McGill University in Professor David Junker's lab. From this first meeting, we knew that Milad was a special, mission-driven founder who set out to power the next generation proteomic sequencing. We were really impressed with Milad and his team and led nomic's pre-seed round.
We are all familiar with sequencing genes - the basic blocks of human heredity. Genes, of course, are incredibly important, but they describe a static state of human body. To enable precision medicine, it is necessary to quickly and affordably measure our dynamic state - the proteins.
Measuring proteins quickly and precisely is a hard problem. There are about 20,000 of them, of which 2,000 are known and useful for medicine. Until nomic, these measurements were costly and slow. nomic's unique nELISA technology combines DNA nanotechnology with spectral multiplexing and automation. nELISA is already revolutionizing the field of proteomics by measuring 1,000 proteins across 1,000 samples at a fraction of the cost.
nomic just announced that it closed $17M series A led by LuxCapital, and 2048 Ventures is excited to participate and continue to help build this important business.
nomic will deploy the new capital to grow the teams in Montreal and Boston, expand access to the platform by increasing profiling capacity to 100,000 samples a quarter by Q2 2022, scale the nELISA to 500 on-boarded proteins, as well as begin the development of various new modalities such as the identification of post-translational modification.
Milad and nomic's team are on their way to fulfill their mission - to make the human proteome as broadly and easily accessible as the human genome.
Subscribe to our newsletter
Signup to get quarterly updates and important announcements from 2048 Ventures.